This role is considered Virtual.
- HCP Support in Diagnosing the Disease: Partner with cardiologists, neurologists, and other key HCPs to deliver scientific and clinical education that aids in the early and accurate diagnosis of transthyretin amyloidosis.
- Clinical Data Delivery : Present and explain complex scientific data in a clear, accessible manner to ensure HCPs fully understand the diagnostic tools and methodologies.
- Product Promotion: Once diagnosis is established, introduce and promote our transthyretin amyloidosis products as a key solution for patient management. Ensure HCPs understand its clinical benefits.
- Support Product Launch: Assist in the launch of our next indication, particularly with cardiologists, by building awareness, sharing data, and facilitating market adoption.
- Optimize Patient Access and Relationship Building : Serve as a key educational resource for all relevant stakeholders to help navigate reimbursement and patient access challenges, ensuring timely and effective patient access to Alnylam’s therapies. Develop strong relationships with key HCPs and hospital pharmacists, navigating access challenges and ensuring product adoption where necessary. Autonomy in Territory Management: Lead and manage your own territory and key account plans, developing strategies to educate HCPs while driving business objectives.
- Life Science Education : University degree in a business-related field such as life sciences, medicine or comparable educational background.
- Certified Medical Representative ( Pharmareferentenprüfung )
- Sales and Scientific Communication Experience: Proven success in pharmaceutical, biotech, or healthcare sales, especially in supporting HCPs with scientific and diagnostic knowledge. Experience with rare diseases is a plus. A strong network in cardiology is desired.
- Diagnostic Focus: Ability to engage HCPs on the front lines of diagnosis, using clinical data and insights to support early disease identification.
- Access Knowledge: Strong knowledge of the reimbursement landscape and the practice management environment. Prior Austrian Market Access experience is desired. Austrian healthcare policy experience is a plus.
- Entrepreneurial Spirit: A self-starter who thrives in a dynamic environment, eager to make a direct impact on patient outcomes and with a strong business acumen to add value to the existing health care structures.
- Relationship-Driven: A natural networker with a talent for building and maintaining professional relationships with HCPs.
- Business Travel: Ability to travel within territory on a regular basis (80% of the time) including occasional overnight and weekend travel (eg. to attend relevant congresses or key events) if required. Must hold a valid driver's license.
- Microsoft Office Skills: Proficient knowledge in Excel, PowerPoint, Word, etc. for project work and team collaboration are essential.
- Fluent in German and English, both written and verbal.
About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.